DE60211464D1 - Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung - Google Patents

Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung

Info

Publication number
DE60211464D1
DE60211464D1 DE60211464T DE60211464T DE60211464D1 DE 60211464 D1 DE60211464 D1 DE 60211464D1 DE 60211464 T DE60211464 T DE 60211464T DE 60211464 T DE60211464 T DE 60211464T DE 60211464 D1 DE60211464 D1 DE 60211464D1
Authority
DE
Germany
Prior art keywords
preparation
active ingredient
pharmaceutical formulations
acid polymer
ingredient containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60211464T
Other languages
English (en)
Other versions
DE60211464T3 (de
DE60211464T2 (de
Inventor
Kazumichi Yamamoto
Akiko Yamada
Yoshio Hata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26617910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60211464(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE60211464D1 publication Critical patent/DE60211464D1/de
Application granted granted Critical
Publication of DE60211464T2 publication Critical patent/DE60211464T2/de
Publication of DE60211464T3 publication Critical patent/DE60211464T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Moulds For Moulding Plastics Or The Like (AREA)
DE60211464T 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung Expired - Lifetime DE60211464T3 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001199484 2001-06-29
JP2001199484 2001-06-29
JP2001340993 2001-11-06
JP2001340993 2001-11-06
PCT/JP2002/006527 WO2003002092A2 (en) 2001-06-29 2002-06-28 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same

Publications (3)

Publication Number Publication Date
DE60211464D1 true DE60211464D1 (de) 2006-06-22
DE60211464T2 DE60211464T2 (de) 2006-09-07
DE60211464T3 DE60211464T3 (de) 2011-03-17

Family

ID=26617910

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60225481T Expired - Lifetime DE60225481T2 (de) 2001-06-29 2002-06-28 Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung
DE60211464T Expired - Lifetime DE60211464T3 (de) 2001-06-29 2002-06-28 Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60225481T Expired - Lifetime DE60225481T2 (de) 2001-06-29 2002-06-28 Pharmazeutische Formulierungen mit kontrollierter Wirkstoff-Freigabe enthaltend Milchsäure-Polymer und Hydroxynaphthalin-Carbonsäure, sowie deren Herstellung

Country Status (34)

Country Link
US (4) US7429559B2 (de)
EP (3) EP1330293B2 (de)
JP (5) JP2003206240A (de)
KR (2) KR100916173B1 (de)
CN (3) CN100577206C (de)
AR (2) AR034641A1 (de)
AT (3) ATE387937T1 (de)
AU (2) AU2002311631B2 (de)
BR (1) BRPI0210561B8 (de)
CA (1) CA2455392C (de)
CO (1) CO5540367A2 (de)
CR (1) CR11283A (de)
CY (2) CY1105071T1 (de)
CZ (1) CZ306327B6 (de)
DE (2) DE60225481T2 (de)
DK (2) DK1949936T3 (de)
ES (2) ES2263788T5 (de)
HK (1) HK1056332A1 (de)
HU (1) HU230351B1 (de)
IL (3) IL159059A0 (de)
MX (1) MXPA03011456A (de)
MY (1) MY142066A (de)
NO (1) NO331883B1 (de)
NZ (2) NZ541884A (de)
PE (1) PE20030066A1 (de)
PL (1) PL204903B1 (de)
PT (2) PT1949936E (de)
RU (1) RU2301661C2 (de)
SG (1) SG180015A1 (de)
SI (1) SI1949936T1 (de)
SK (1) SK287577B6 (de)
TW (2) TWI332407B (de)
WO (1) WO2003002092A2 (de)
ZA (1) ZA200309152B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0100221A3 (en) * 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
ES2605402T3 (es) 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
BRPI0409032A (pt) * 2003-04-10 2006-05-02 Pr Pharmaceuticals método para a produção de micropartìculas à base de emulsão
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US8871269B2 (en) * 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
CA2533592C (en) * 2003-07-23 2015-11-10 Pr Pharmaceuticals, Inc. Controlled release compositions
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070149457A1 (en) * 2005-12-13 2007-06-28 Byron Rubin Stable solid forms of enterostatin
CN101400363B (zh) 2006-01-18 2012-08-29 昌达生物科技公司 具有增强的稳定性的药物组合物
US7858663B1 (en) * 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
BRPI0720582B1 (pt) 2006-12-18 2021-08-24 Takeda Pharmaceutical Company Limited Composição de liberação prolongada, processo para a preparação da mesma, composição farmacêutica, agente profilático ou terapêutico, e, uso de uma substância fisiologicamente ativa
US20110319987A1 (en) * 2009-05-20 2011-12-29 Arsenal Medical Medical implant
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
EP3079668A1 (de) 2013-12-09 2016-10-19 Durect Corporation Pharmazeutisch aktive wirkstoffkomplexe, polymerkomplexe und zusammensetzungen und verfahren damit
CN103751851A (zh) * 2014-01-17 2014-04-30 东华大学 一种无机/有机多药物控释复合纳米纤维支架的制备方法
KR101558083B1 (ko) * 2014-04-07 2015-10-07 에스케이케미칼주식회사 약물함유 고분자미립구 제조방법
US9956164B2 (en) 2014-04-16 2018-05-01 Veyx-Pharma Gmbh Veterinary pharmaceutical composition and use thereof
US10787920B2 (en) 2016-10-12 2020-09-29 General Electric Company Turbine engine inducer assembly
KR102089737B1 (ko) * 2017-11-01 2020-03-16 한국화학연구원 에씨탈로프람을 함유한 미립구형 서방출 주사제 및 그의 제조방법
WO2024095158A1 (en) 2022-10-31 2024-05-10 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3755558A (en) 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4258063A (en) 1978-06-23 1981-03-24 Henkel Corporation Self-emulsifying cosmetic base
US4249531A (en) 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4479911A (en) 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4539981A (en) 1982-11-08 1985-09-10 Johnson & Johnson Products, Inc. Absorbable bone fixation device
FR2537980B1 (fr) 1982-12-17 1986-12-19 Sandoz Sa Derives d'acides hydroxycarboxyliques oligomeres, leur preparation et leur utilisation
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPH0678425B2 (ja) 1984-07-06 1994-10-05 和光純薬工業株式会社 重合体の新規製造法
CA1256638A (en) 1984-07-06 1989-06-27 Motoaki Tanaka Polymer and its production
EP0190833B1 (de) 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von Mikrokapseln
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
DE69129770T2 (de) * 1990-04-13 1998-11-19 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare Polymere, ihre Herstellung und ihre Verwendung
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
US5353086A (en) * 1993-05-03 1994-10-04 Eastman Kodak Company Textured surface with canted channels for an automatic tray processor
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
JP3490171B2 (ja) 1994-02-21 2004-01-26 武田薬品工業株式会社 生体内分解性ポリマーの末端カルボキシル基におけるエステル
DE69508985T2 (de) * 1994-02-21 1999-08-19 Takeda Chemical Industries Ltd Polyester Matrix für eine pharmazeutische Zusammensetzung mit verzögerter Freigabe
US5763513A (en) 1994-05-19 1998-06-09 Mitsui Toatsu Chemicals, Inc. L-lactic acid polymer composition, molded product and film
JPH08259460A (ja) * 1995-01-23 1996-10-08 Takeda Chem Ind Ltd 徐放性製剤の製造法
JP3902272B2 (ja) * 1995-09-04 2007-04-04 武田薬品工業株式会社 徐放性製剤の製造法
US5922662A (en) * 1996-08-07 1999-07-13 Colgate Palmolive Company High foaming nonionic surfactant based liquid detergent
PT839525E (pt) * 1996-10-31 2004-10-29 Takeda Chemical Industries Ltd Preparacao de libertacao prolongada
JPH10273447A (ja) * 1997-01-29 1998-10-13 Takeda Chem Ind Ltd 徐放性マイクロスフィア、その製造法および用途
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
HUP0100221A3 (en) * 1998-01-16 2002-11-28 Takeda Pharmaceutical Sustained release compositions, process for producing the same and utilization thereof
JPH11269094A (ja) 1998-01-16 1999-10-05 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
US6114495A (en) 1998-04-01 2000-09-05 Cargill Incorporated Lactic acid residue containing polymer composition and product having improved stability, and method for preparation and use thereof
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
CN1134479C (zh) * 1998-12-15 2004-01-14 武田药品工业株式会社 制备聚合物的方法
JP2000238051A (ja) † 1999-02-23 2000-09-05 Kansei Corp 表皮シートの発泡成形型へのセッティング方法
AU5853000A (en) * 1999-07-15 2001-02-05 Takeda Chemical Industries Ltd. Sustained release compositions, process for producing the same and use thereof
JP2001081043A (ja) * 1999-07-15 2001-03-27 Takeda Chem Ind Ltd 徐放性組成物、その製造法および用途
JP3837607B2 (ja) † 2000-05-29 2006-10-25 Ｔｃｍ株式会社 マスト用溶接位置決め治具
ES2256276T5 (es) 2000-08-07 2011-02-22 Wako Pure Chemical Industries, Ltd. Polímero de ácido láctico y procedimiento para su producción.
AU2002218494A1 (en) * 2000-11-29 2002-06-11 Takeda Chemical Industries Ltd. Medicinal compositions and process for producing the same
WO2002047722A1 (fr) * 2000-12-15 2002-06-20 Takeda Chemical Industries, Ltd. Compositions medicinales agoniste ou antagoniste de la gonadoliberine non peptidyl, methode de production et utilisation desdites compositions
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same

Also Published As

Publication number Publication date
CN1292796C (zh) 2007-01-03
CN1724066A (zh) 2006-01-25
IL159059A0 (en) 2004-05-12
EP1330293B2 (de) 2010-10-27
SK287577B6 (sk) 2011-03-04
EP1491236B1 (de) 2008-03-05
EP1330293A2 (de) 2003-07-30
WO2003002092A2 (en) 2003-01-09
JP4819173B2 (ja) 2011-11-24
US20120283187A1 (en) 2012-11-08
CN1868458A (zh) 2006-11-29
TWI332407B (en) 2010-11-01
PT1330293E (pt) 2006-08-31
CR11283A (es) 2010-05-31
JP2004238400A (ja) 2004-08-26
US20090005318A1 (en) 2009-01-01
TW200526267A (en) 2005-08-16
DE60211464T3 (de) 2011-03-17
PE20030066A1 (es) 2003-03-20
CA2455392C (en) 2011-11-22
CZ306327B6 (cs) 2016-12-07
IL159059A (en) 2011-06-30
US8246987B2 (en) 2012-08-21
DK1949936T3 (da) 2011-08-15
EP1949936A2 (de) 2008-07-30
JP2003206240A (ja) 2003-07-22
DK1330293T3 (da) 2006-09-11
DE60225481T2 (de) 2009-02-26
PT1949936E (pt) 2011-07-12
ES2263788T3 (es) 2006-12-16
HUP0400378A2 (hu) 2004-12-28
WO2003002092A3 (en) 2003-04-10
EP1949936A3 (de) 2008-10-08
RU2004102507A (ru) 2005-03-10
HUP0400378A3 (en) 2010-01-28
HU230351B1 (hu) 2016-02-29
SG180015A1 (en) 2012-05-30
NO20035738L (no) 2004-02-27
ES2366677T3 (es) 2011-10-24
AR098261A2 (es) 2016-05-18
SK15602003A3 (sk) 2004-06-08
KR20090020708A (ko) 2009-02-26
ZA200309152B (en) 2005-01-26
ATE326264T1 (de) 2006-06-15
US8067030B2 (en) 2011-11-29
JP2009167203A (ja) 2009-07-30
BRPI0210561B8 (pt) 2021-05-25
US20030134800A1 (en) 2003-07-17
CZ20033493A3 (cs) 2004-08-18
CO5540367A2 (es) 2005-07-29
HK1056332A1 (en) 2004-02-13
AU2002311631B2 (en) 2007-02-08
US20110166084A1 (en) 2011-07-07
NZ529969A (en) 2005-10-28
SI1949936T1 (sl) 2011-08-31
CN1535168A (zh) 2004-10-06
MY142066A (en) 2010-08-30
PL367518A1 (en) 2005-02-21
AU2006246508A1 (en) 2006-12-21
EP1491236A1 (de) 2004-12-29
JP2010189427A (ja) 2010-09-02
CN100577206C (zh) 2010-01-06
US7429559B2 (en) 2008-09-30
ES2263788T5 (es) 2011-02-22
CN100348265C (zh) 2007-11-14
KR100961413B1 (ko) 2010-06-09
AU2006246508B2 (en) 2008-09-04
BR0210561A (pt) 2004-06-22
DK1330293T4 (da) 2011-01-10
MXPA03011456A (es) 2004-07-01
RU2301661C2 (ru) 2007-06-27
PL204903B1 (pl) 2010-02-26
NO20035738D0 (no) 2003-12-19
AR034641A1 (es) 2004-03-03
ATE387937T1 (de) 2008-03-15
CA2455392A1 (en) 2003-01-09
EP1949936B1 (de) 2011-05-18
KR20040018402A (ko) 2004-03-03
DE60211464T2 (de) 2006-09-07
JP4819172B2 (ja) 2011-11-24
DE60225481D1 (de) 2008-04-17
ATE509668T1 (de) 2011-06-15
KR100916173B1 (ko) 2009-09-08
IL186782A0 (en) 2008-02-09
US8815801B2 (en) 2014-08-26
CY1111708T1 (el) 2015-10-07
CY1105071T1 (el) 2010-03-03
NO331883B1 (no) 2012-04-23
NZ541884A (en) 2007-01-26
BRPI0210561B1 (pt) 2018-08-14
JP2010189428A (ja) 2010-09-02
EP1330293B1 (de) 2006-05-17

Similar Documents

Publication Publication Date Title
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
DE60142890D1 (de) 3-aminoazetidinderivate enthaltende pharmazeutische zusammensetzungen, diese derivate und deren herstellung
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
EP2322146A3 (de) Mikrokapselformulierung mit zwei pharmazeutischen Wirkstoffen
ATE355829T1 (de) Einen lipophilen wirkstoff enthaltende feste pharmazeutische zusammensetzung sowie deren herstellung
DE60232147D1 (de) Pharmazeutische zubereitung mit verzögerter wirkstoff-freisetzung enthaltend milchsäure-glycolsäure copolymer, und verfahren zu deren herstellung
DE60318188D1 (de) Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
ATE233752T1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
DE60005819D1 (de) Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
BRPI0611400B1 (pt) formulações contendo xiloglicano muco-adesivas úteis em dispositivos médicos e em formulações farmacêuticas
ATE396198T1 (de) 17alpha-alkyl-17beta-oxy-estratriene und zwischenprodukte zu deren herstellung, verwendung der 17alpha-alkyl-17beta-oxy-estratriene zur herstellung von arzneimitteln sowie pharmazeutische präparate
EE05311B1 (et) Meetod mineraalse t„iteaine t””tlemiseks poldialklsiloksaani ja rasvhappega, saades hdrofoobsed t„iteained, ja nende kasutamine polmeerides ''hingavate'' kilede jaoks
ATE324104T1 (de) Mesalazine enthaltende pharmazeutische zusammensetzungen mit gesteuerter freisetzung
ITFI930247A0 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
BR0210489A (pt) Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
ATE367803T1 (de) Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
ATE469644T1 (de) Pharmazeutische zubereitung enthaltend n-ä2-(1,6, 7,8-tetrahydro-2h-indenoä5,4 büfuran-8- yl)ethylüpropionamid ummantelt mit einer copolyvidon-enthaltenden, polyäthylenglykolfreien umhüllung
WO2001013898A3 (en) Pharmaceutical formulations with different release times
ATE303137T1 (de) Pharmazeutische zusammensetzung zur orale verabreichung mit verbesserter bioverfügbarkeit
DE60109279D1 (de) Pharmazeutische zusammensetzungen mit oligosacchariden und deren herstellung
SE0001916D0 (sv) Novel formulation

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings